AFEYAN NOUBAR

Director Afeyan buys 4,687,500 GENB shares for $75,000,000.00 in 3 transactions at $16.00 post-IPO; cluster buy pattern detected

Director Noubar Afeyan completed 3 separate purchases totaling 4,687,500 shares for $75,000,000.00 at $16.00 on 2026-03-02, just two trading days after GENB's recent listing. The transaction brought his post-transaction holdings to 1,562,500 shares. Notably, 3 other insiders have also bought within the past 14 days, establishing a cluster buy pattern at the company. The filing contains derivative security conversions, indicating the full position context extends beyond Table I and requires deeper review of the derivative holdings structure.

Director Afeyan Noubar purchases 4,687,500 shares for $75,000,000 in 3 transactions at $16.00 amid cluster buy pattern at newly-listed GENB.

Afeyan Noubar, a director at Generate Biomedicines, executed 3 separate purchases totaling 4,687,500 shares for $75,000,000.00 on 2026-03-02 at $16.00 per share—the IPO/recent-listing price—while the stock trades at $12.17 currently, a 23.8% decline from transaction price. The purchase is material in scale and occurs in a cluster context: 3 other insiders also bought within the past 14 days, suggesting coordinated insider accumulation at the open-market reference price. This filing involves a derivative-conversion transaction (Form 4 Table II not yet populated), so the post-transaction holding of 1,562,500 shares does not represent the director's full economic stake. The magnitude of the buy, the cluster pattern among directors, and the immediate price deterioration post-listing warrant investor attention to underlying fundamentals and the signal these insider actions send about medium-term valuation expectations.

Director Afeyan sold 15,000 MRNA shares for $1.8M at $119.96 avg on 2024-07-31; stock down 48.0% from 52-week high

AFEYAN NOUBAR, a Director, executed 4 separate sales totaling 15,000 shares for $1,799,442.81 on 2024-07-31, with prices ranging from $118.96 to $121.62. This represents a 0.7% reduction in his 2.24M-share position. The timing coincides with substantial deterioration in Moderna's fundamental outlook: revenue of $241,000,000.00 for the latest quarter represents a -64.4% annual decline, the company reported net income of $-1,279,000,000.00 over its most recent full fiscal year, and the stock has declined 25.3% in the 30 days and 30.7% in the 90 days since the sale was executed, falling 48.0% from its 52-week high of $166.61. His cross-ticker track record across 20 prior open-market sales shows an average 30-day return of -4.0%, though outcomes from his 5 recent trades at MRNA are not yet measurable.

Director Afeyan sells 15,000 MRNA shares across 4 transactions for $1,766,972.01; holds 2.24M post-sale

Noubar Afeyan sold 15,000 shares (0.7% of pre-transaction holdings) on 2024-07-24 at a blended average price of $117.80, generating $1,766,972.01. This comes immediately after a series of five separate sales by the same director on 2024-07-17, suggesting sustained liquidation activity over consecutive trading days. Moderna's fundamentals show acute stress: the company reported negative net income of $-1.2B over its most recent full fiscal year, revenue of $167.0M in the latest quarter, and annual revenue growth of -64.4%, indicating a sharp decline in business traction. The stock currently trades at $122.11, modestly above the transaction prices but -26.7% from its 52-week high of $166.61. Afeyan's cross-ticker track record shows 20 prior sales with an average 90-day return of -4.5%, suggesting his recent sells at other companies have preceded declines; however, outcomes at MRNA specifically remain unmeasurable (the five prior MRNA sales from 2024-07-17 are too recent to assess 30- or 90-day performance).

Moderna Director Afeyan sells 15,000 shares for $1.8M on 2024-07-17 amid -64.4% revenue decline and $-1.2B net loss.

Noubar Afeyan executed 5 separate sales totaling 15,000 shares for $1,842,650.58 at an average price of $122.84, reducing his holdings by 0.7% to 2.25M shares. The stock has declined 27.3% from its 52-week high of $166.61 and is down 9.1% over the prior 30 days, though up 19.5% over 90 days. Most significantly, Moderna's fundamentals have deteriorated sharply: annual revenue contracted 64.4%, the company reported a $-1.2B net loss in the latest fiscal year, and the most recent quarterly revenue stands at only $167.0M. Afeyan's cross-ticker track record shows 20 prior sells with an average 30-day return of -9.6%, and he executed 5 sales at MRNA just one week prior (2024-07-10), establishing a pattern of consistent selling activity in early July. This sustained selling activity, combined with the company's steep revenue collapse and operating losses, signals substantial pressure on cash generation and may reflect views on near-term recovery prospects in a highly competitive vaccine market.

Director Noubar Afeyan sold 15,000 MRNA shares on 2024-07-10 for $1.8M; stock down 17.8% in past 30 days

Noubar Afeyan, a director at Moderna, executed 5 separate sales totaling 15,000 shares (15.0K shares) for $1,756,176.98 ($1.8M) on 2024-07-10, at a blended average price of $117.08. His post-transaction holding of 2.27M shares represents a -0.7% reduction versus his pre-transaction position of 2.28M shares. The stock has declined 17.8% over the past 30 days and is trading 27.1% below its 52-week high of $166.61. Moderna's fundamentals show Revenue of $167,000,000.00 for the latest quarter with a Net income of $-1,175,000,000.00, alongside Annual revenue growth of -64.4%, indicating significant operational headwinds. Afeyan's prior 5 trades at MRNA on 2024-06-26 are too recent to have measurable 30-day or 90-day outcomes, and his cross-ticker track record shows 20 prior sells with an average 30-day return of -17.3%, neither confirming nor contradicting a pattern of well-timed exits at this particular security.

Director Afeyan sells 15,000 MRNA shares for $1.9M at blended $127.22; stock now -28.7% from 52-week high.

Noubar Afeyan executed 10 separate sales on 2024-06-26 totaling 15,000 shares for $1,908,293.42, reducing his holdings from 2,299,015 to 2,284,015 shares (a -0.7% reduction). The blended average transaction price was $127.22, yet Moderna's current stock price is $118.75, down 28.7% from its 52-week high of $166.61 and down 19.7% over the past 30 days. The company faces fundamental headwinds: annual revenue contracted 64.4% year-over-year, the most recent quarter generated $167.0M in revenue against a net loss of $1.2B, and Moderna remained unprofitable over its most recent full fiscal year. This large multi-tranche sale by a director occurred just 8 days before the Form 4 filing and preceded a sharp deterioration in stock price; the timing context warrants attention given the magnitude of the transaction and the severity of the company's current financial position.

Director Noubar Afeyan sold 15,000 MRNA shares for $2.0M on 2024-06-18; stock -19.9% from 52-week high, revenue down -64.4% YoY

Noubar Afeyan executed 5 separate sales totaling 15,000 shares for $2,003,561.28 at blended average price $133.57 on June 18, 2024, reducing his holdings by 0.6% to 2,299,015 shares. The timing coincides with significant headwinds: Moderna's stock has declined 19.9% from its 52-week high of $166.61, revenue contracted 64.4% year-over-year to $167.0M in the latest quarter, and the company posted a net loss of $1,175,000,000.00 for its most recent full fiscal year. This sale follows four earlier Moderna sales on June 12, 2024 (outcomes not yet measurable), establishing a pattern of director selling activity during a period of sharp financial and stock-price deterioration.

Director Afeyan sold 15,000 shares for $2.2M (blended avg $147.20) on 2024-06-12; stock now $140.03, -16.0% from 52-week high.

On 2024-06-12, Noubar Afeyan (Director) executed 8 separate sales totaling 15,000 shares for $2,208,071.31, reducing his holdings by 0.6% to 2,314,015 shares. The sales occurred at prices ranging from $142.97 to $150.24, just below the 52-week high of $166.61. This transaction occurred against a backdrop of significant operational challenges: Moderna reported $167.0M in quarterly revenue with a net loss of $1.2B, and annual revenue contracted 64.4% year-over-year, signaling a dramatic collapse in COVID-vaccine demand post-pandemic. The company remains unprofitable on a full-year basis. With the stock now trading 16.0% below its recent high and Afeyan holding 2.31M shares post-transaction, the sale may reflect assessment of current valuation given deteriorated fundamentals, though the modest 0.6% reduction of a substantial position preserves meaningful retained equity.